• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aligos Therapeutics Inc (NQ: ALGS )

    0.3500 -0.0284 (-7.51%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,508,754
    Open 0.3750
    Bid (Size) 0.3500 (25)
    Ask (Size) 0.3900 (30)
    Prev. Close 0.3784
    Today's Range 0.3482 - 0.3840
    52wk Range 0.3482 - 1.200
    Shares Outstanding 42,940,089
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
    From Aligos Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    -50.66%
    -50.66%
    1 Month
    -40.68%
    -40.68%
    3 Month
    -63.21%
    -63.21%
    6 Month
    -50.66%
    -50.66%
    1 Year
    -65.00%
    -65.00%

    More News

    Read More
    Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
    From Aligos Therapeutics
    Via GlobeNewswire
    Recap: Aligos Therapeutics Q4 Earnings
    Via Benzinga
    Aligos Therapeutics Earnings Preview
    Via Benzinga
    ALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024
    Via InvestorPlace
    Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
    From Aligos Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    Earnings Scheduled For March 12, 2024
    Via Benzinga
    Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
    From Aligos Therapeutics
    Via GlobeNewswire
    Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
    From Aligos Therapeutics
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.